Ludwig Hantson is CEO at ALEXION PHARMACEUTICALS, INC. (ALXN). They have made 4 open-market trades across 1 company since 2012, most recently 2026-02-26.
CIK 0001491435
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.2M since 2017, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALXN | SELL | 2018-12-31 | 2019-01-03 | $95.85 | $622K | +9.7% | +21.5% | +37.4% |
| ALXN | SELL | 2018-02-08 | 2018-02-08 | $116.31 | $3.1M | +7.4% | +16.5% | +7.1% |
| ALXN | SELL | 2018-01-02 | 2018-01-04 | $121.63 | $621K | -1.4% | -9.0% | -10.0% |
| ALXN | BUY | 2017-06-14 | 2017-06-19 | $116.72 | $1.2M | +4.6% | +8.8% | +22.8% |
| BAX | SELL · 10b5-1 | 2014-07-09 | 2014-07-11 | $76.00 | $1.9M | -7.5% | -1.3% | -1.3% |
| BAX | SELL · 10b5-1 | 2013-01-28 | 2013-01-29 | $67.64 | $710K | -7.5% | -1.3% | -1.3% |
| BAX | SELL · 10b5-1 | 2012-09-25 | 2012-09-27 | $61.54 | $2.2M | -7.5% | -1.3% | -1.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.